JP2010524914A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010524914A5 JP2010524914A5 JP2010503606A JP2010503606A JP2010524914A5 JP 2010524914 A5 JP2010524914 A5 JP 2010524914A5 JP 2010503606 A JP2010503606 A JP 2010503606A JP 2010503606 A JP2010503606 A JP 2010503606A JP 2010524914 A5 JP2010524914 A5 JP 2010524914A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heterocycloalkyl
- group
- cycloalkyl
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91259707P | 2007-04-18 | 2007-04-18 | |
| US60/912,597 | 2007-04-18 | ||
| PCT/IB2008/000845 WO2008129380A1 (en) | 2007-04-18 | 2008-04-07 | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010524914A JP2010524914A (ja) | 2010-07-22 |
| JP2010524914A5 true JP2010524914A5 (enExample) | 2011-05-19 |
| JP4782239B2 JP4782239B2 (ja) | 2011-09-28 |
Family
ID=39646361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010503606A Active JP4782239B2 (ja) | 2007-04-18 | 2008-04-07 | 異常細胞増殖治療のためのスルホニルアミド誘導体 |
Country Status (32)
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20125581B (en) | 2007-04-18 | 2012-07-25 | Pfizer Prod Inc | Sulfonyl amide derivatives for treatment of abnormal cell growth |
| EP2268621A1 (en) * | 2008-03-20 | 2011-01-05 | Boehringer Ingelheim International GmbH | Regioselective preparation of substituted pyrimidines |
| UY31714A (es) * | 2008-03-20 | 2009-11-10 | Boehringer Ingelheim Int | Preparación selectiva de pirimidinas sustituidas |
| US20100056524A1 (en) * | 2008-04-02 | 2010-03-04 | Mciver Edward Giles | Compound |
| CN102203080A (zh) * | 2008-09-03 | 2011-09-28 | 拜尔农作物科学股份公司 | 作为杀菌剂的杂环取代的苯胺基嘧啶 |
| UY32240A (es) * | 2008-11-14 | 2010-06-30 | Boeringer Ingelheim Kg | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. |
| JP2010111702A (ja) * | 2009-02-16 | 2010-05-20 | Tetsuya Nishio | 複素環化合物、その製造法および用途 |
| CN101812016B (zh) * | 2009-02-23 | 2013-01-16 | 浙江海翔药业股份有限公司 | 一种制备依托昔布中间体-6-甲基烟酸及其酯的方法 |
| EP2261211A1 (en) * | 2009-05-20 | 2010-12-15 | Université de Lille 2 Droit et Santé | 1,4-dihydropyridine derivatives and their uses |
| TW201100441A (en) * | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| TWI500614B (zh) | 2009-06-05 | 2015-09-21 | Cephalon Inc | １，２，４－三唑並〔１，５ａ〕吡啶衍生物之製備和用途 |
| US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
| EP2464633A1 (en) | 2009-08-14 | 2012-06-20 | Boehringer Ingelheim International GmbH | Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives |
| WO2011107585A1 (en) | 2010-03-04 | 2011-09-09 | Cellzome Limited | Morpholino substituted urea derivatives as mtor inhibitors |
| CN103003264B (zh) | 2010-05-21 | 2014-08-06 | 切米利亚股份公司 | 嘧啶衍生物 |
| JP5713367B2 (ja) * | 2010-06-04 | 2015-05-07 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｌｒｒｋ２モジュレーターとしてのアミノピリミジン誘導体 |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| US9133224B2 (en) | 2010-11-29 | 2015-09-15 | OSI Pharmaceuticals, LLC | Macrocyclic kinase inhibitors |
| CN103534240B (zh) | 2011-02-17 | 2015-12-09 | 癌症疗法Crc私人有限公司 | 选择性fak抑制剂 |
| CA2827171C (en) | 2011-02-17 | 2019-04-09 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| US9006241B2 (en) | 2011-03-24 | 2015-04-14 | Noviga Research Ab | Pyrimidine derivatives |
| DK2699553T3 (da) | 2011-04-22 | 2024-01-29 | Signal Pharm Llc | Substituerede diaminocarboxamid- og diaminocarbonitrilpyrimidiner, sammensætninger deraf og fremgangsmåder til behandling dermed |
| BR112014000360A2 (pt) * | 2011-07-28 | 2017-02-14 | Cellzome Ltd | análogos de heterociclil pirimidina como inibidores jak |
| RU2564419C1 (ru) * | 2011-07-28 | 2015-09-27 | Целльзом Лимитид | Гетероциклические аналоги пиримидина в качестве ингибиторов jak |
| AU2012311458B2 (en) | 2011-09-21 | 2016-02-04 | Cellzome Limited | Morpholino substituted urea or carbamate derivatives as mTOR inhibitors |
| MX341577B (es) | 2011-10-07 | 2016-08-25 | Cellzome Ltd | Derivados biciclicos de pirimidin-urea o carbamato sustituidos con morfolino como inhibidores del blanco de rapamicina de mamifero. |
| JP2015500862A (ja) | 2011-12-23 | 2015-01-08 | セルゾーム リミティッド | キナーゼ阻害剤としてのピリミジン−２，４−ジアミン誘導体 |
| DK2822939T3 (en) * | 2012-03-06 | 2016-03-14 | Cephalon Inc | CONDENSED BICYCLEIC 2,4-DIAMINOPYRIMIDINE DERIVATIVES AS DUAL ALK AND FAK INHIBITORS |
| CN104507929B (zh) | 2012-05-24 | 2018-02-16 | 赛尔佐姆有限公司 | 作为tyk2抑制剂的杂环基嘧啶类似物 |
| MX384259B (es) * | 2014-01-09 | 2025-03-14 | Verastem Inc | Composiciones y metodos para tratamiento de crecimiento celular anormal. |
| NZ715903A (en) | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
| ES2945387T3 (es) | 2014-02-07 | 2023-06-30 | Verastem Inc | Procedimientos y composiciones para tratar el crecimiento celular anormal |
| TN2016000503A1 (en) | 2014-05-14 | 2018-04-04 | Pfizer | Pyrazolopyridines and pyrazolopyrimidines |
| NZ732793A (en) | 2014-12-16 | 2023-07-28 | Signal Pharm Llc | Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide |
| JP6903577B2 (ja) | 2014-12-16 | 2021-07-14 | シグナル ファーマシューティカルズ，エルエルシー | 皮膚におけるｃ−Ｊｕｎ Ｎ末端キナーゼの阻害の測定方法 |
| WO2016100452A2 (en) * | 2014-12-17 | 2016-06-23 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| EP3250557B1 (en) | 2015-01-29 | 2024-11-20 | Signal Pharmaceuticals, LLC | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| CN114209841A (zh) | 2015-06-29 | 2022-03-22 | 维瑞斯特姆股份有限公司 | 治疗组合物、组合和使用方法 |
| CN107922287B (zh) | 2015-07-24 | 2021-04-09 | 细胞基因公司 | 合成(1r,2r,5r)-5-氨基-2-甲基环己醇盐酸盐的方法和其中可用的中间体 |
| CN105111204B (zh) * | 2015-08-14 | 2016-09-14 | 天津小新医药科技有限公司 | 吡啶盐类酪氨酸激酶抑制剂、制备方法及其用途 |
| CN105153150B (zh) * | 2015-08-14 | 2016-09-14 | 天津小新医药科技有限公司 | 一类吡啶盐类jak抑制剂、制备方法及其用途 |
| CN105503860B (zh) * | 2015-10-13 | 2017-03-01 | 天津小新医药科技有限公司 | 一类腈基取代的吡啶盐类jak抑制剂、制备方法及其用途 |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| CN106279011A (zh) * | 2016-08-16 | 2017-01-04 | 成都百事兴科技实业有限公司 | 一种2,4‑二羟基‑6‑甲基烟酸乙酯的制备方法 |
| WO2019117813A1 (en) * | 2017-12-15 | 2019-06-20 | National University Of Singapore | Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis |
| BR112020018585A8 (pt) | 2018-03-12 | 2022-12-06 | Inst Nat Sante Rech Med | Uso de mimeticos de restrição calórica para potencializar a quimioimunoterapia para o tratamento de câncer |
| JP2021528370A (ja) * | 2018-05-07 | 2021-10-21 | ヒノバ ファーマシューティカルズ インコーポレイテッド | 重水素化デファクチニブ化合物及びその使用 |
| WO2020006724A1 (zh) * | 2018-07-05 | 2020-01-09 | 清华大学 | 一种靶向降解fak蛋白的化合物及其应用 |
| US20220040317A1 (en) * | 2018-09-27 | 2022-02-10 | Dana-Farber Cancer Institute, Inc. | Degradation of fak or fak and alk by conjugation of fak and alk inhibitors with e3 ligase ligands and methods of use |
| KR102709127B1 (ko) * | 2018-12-27 | 2024-09-24 | 하이노바 파마슈티컬스 인코포레이티드 | Fak 억제제 및 그 약물 조합물 |
| WO2021047783A1 (en) | 2019-09-13 | 2021-03-18 | The Institute Of Cancer Research: Royal Cancer Hospital | Vs-6063 in combination with ch5126766 for the treatment of cancer |
| CN115151252B (zh) * | 2020-03-02 | 2024-08-27 | 维泰瑞隆有限公司 | 铁死亡抑制剂-二芳基胺对乙酰胺类 |
| CA3202990A1 (en) * | 2020-11-27 | 2022-06-02 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Aminoheteroaryl kinase inhibitors |
| CN112592318B (zh) * | 2020-12-12 | 2022-05-03 | 贵州医科大学 | 2-(4-甲氨酰基)苯胺基-4-氨基嘧啶衍生物及应用 |
| CN112624966B (zh) * | 2020-12-25 | 2022-12-23 | 杭州澳赛诺生物科技有限公司 | 一种2-氨甲基-4-甲基-5-吡啶羧酸的合成方法 |
| WO2022152315A1 (zh) * | 2021-01-18 | 2022-07-21 | 海创药业股份有限公司 | 一种合成氨基嘧啶类fak抑制剂化合物的方法 |
| CN113372334B (zh) * | 2021-05-25 | 2022-05-03 | 贵州医科大学 | 2-(4-甲氨酰基)苯胺基-4-氨基-5-三氟甲基嘧啶衍生物及其应用 |
| US20240277710A1 (en) * | 2021-05-25 | 2024-08-22 | Hinova Pharmaceuticals Inc. | Pharmaceutical composition for treatment of cancer and use thereof |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| CN114716385B (zh) * | 2022-04-08 | 2024-03-12 | 北京师范大学 | 靶向粘着斑激酶的化合物及制备方法和应用 |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| JPWO2024071371A1 (enExample) * | 2022-09-30 | 2024-04-04 | ||
| WO2024249831A2 (en) * | 2023-06-02 | 2024-12-05 | Unogen Biotech Ltd. | Triple kinase inhibitors |
| CN117105916B (zh) * | 2023-10-23 | 2024-01-16 | 希格生科（深圳）有限公司 | 苯并呋喃类化合物及其医药用途 |
| WO2025166180A1 (en) * | 2024-02-02 | 2025-08-07 | Deciphera Pharmaceuticals, Llc | Ulk inhibitors and methods of use thereof |
| WO2025166124A1 (en) * | 2024-02-02 | 2025-08-07 | Deciphera Pharmaceuticals, Llc | Ulk inhibitors and methods of use thereof |
| WO2025199379A1 (en) | 2024-03-22 | 2025-09-25 | Bristol-Myers Squibb Company | Novel fak degrader compounds and uses thereof |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4507146A (en) | 1982-12-28 | 1985-03-26 | Ciba-Geigy Corporation | 2,4-Diamino-6-halo-5-trifluoromethylpyrimidines having herbicidal activity |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| ATE159009T1 (de) | 1991-05-10 | 1997-10-15 | Rhone Poulenc Rorer Int | Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| GB9314884D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
| CN1142817A (zh) | 1993-10-12 | 1997-02-12 | 杜邦麦克制药有限公司 | 1n-烷基-n-芳基嘧啶胺及其衍生物 |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| GB9424233D0 (en) | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| PT821671E (pt) | 1995-04-20 | 2001-04-30 | Pfizer | Derivados do acido arilsulfonil hidroxamico como inibidores de mmp e tnf |
| ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| TW440563B (en) | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
| EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| ID19430A (id) | 1996-07-13 | 1998-07-09 | Glaxo Group Ltd | Senyawa senyawa heterosiklik |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| WO1998003516A1 (en) | 1996-07-18 | 1998-01-29 | Pfizer Inc. | Phosphinate based inhibitors of matrix metalloproteases |
| IL128189A0 (en) | 1996-08-23 | 1999-11-30 | Pfizer | Arylsulfonylamino hydroxamic acid derivatives |
| CA2277100C (en) | 1997-01-06 | 2005-11-22 | Pfizer Inc. | Cyclic sulfone derivatives |
| ID22799A (id) | 1997-02-03 | 1999-12-09 | Pfizer Prod Inc | Turunan-turunan asam arilsulfonilamino hidroksamat |
| AU5493598A (en) | 1997-02-07 | 1998-08-26 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
| BR9807678A (pt) | 1997-02-11 | 2000-02-15 | Pfizer | Derivados de ácidos arilsulfonil-hidroxâmicos |
| CN1171866C (zh) | 1997-08-08 | 2004-10-20 | 辉瑞产品公司 | 芳氧基芳基磺酰氨基异羟肟酸衍生物 |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| KR20010041015A (ko) | 1998-02-17 | 2001-05-15 | 윌리엄 제이. 리플린 | 항바이러스성 피리미딘 유도체 |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| IT1302431B1 (it) * | 1998-08-12 | 2000-09-05 | Alasi Di Arcieri Franco & C S | Dispositivo di controllo di accessi in rete tramite il riconoscimentoveloce di trame applicative che soddisfano un insieme di regole |
| DE69915004T2 (de) | 1998-11-05 | 2004-09-09 | Pfizer Products Inc., Groton | 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate |
| JP2002534498A (ja) | 1999-01-13 | 2002-10-15 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤としてのベンゼンスルホンアミド誘導体およびその使用 |
| EP1081137A1 (en) | 1999-08-12 | 2001-03-07 | Pfizer Products Inc. | Selective inhibitors of aggrecanase in osteoarthritis treatment |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| US6525051B2 (en) | 2000-03-27 | 2003-02-25 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
| EP1282606B1 (en) | 2000-05-08 | 2015-04-22 | Janssen Pharmaceutica NV | Hiv replication inhibiting pyrimidines and triazines |
| JP4969010B2 (ja) | 2000-05-08 | 2012-07-04 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｈｉｖ複製阻害性ピリミジンのプロドラッグ |
| US6630469B2 (en) | 2000-05-09 | 2003-10-07 | Bristol-Myers Squibb Company | 5-HT7 receptor antagonists |
| GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| US6853233B1 (en) * | 2000-09-13 | 2005-02-08 | Infineon Technologies Ag | Level-shifting circuitry having “high” output impedance during disable mode |
| IT1319686B1 (it) | 2000-12-12 | 2003-10-23 | C D Farmasint S R L | Procedimento di preparazione di citalopram. |
| US7625913B2 (en) | 2000-12-21 | 2009-12-01 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| NZ529654A (en) | 2001-05-29 | 2005-12-23 | Schering Ag | CDK inhibiting pyrimidines, production thereof and their use as medicaments |
| WO2002102783A1 (en) | 2001-06-19 | 2002-12-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| JP2005500294A (ja) * | 2001-06-19 | 2005-01-06 | ブリストル−マイヤーズ スクイブ カンパニー | ホスホジエステラーゼ７に対するピリミジン阻害剤 |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| WO2003040141A1 (en) | 2001-09-28 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders |
| JP4460292B2 (ja) | 2001-10-17 | 2010-05-12 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法 |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US7008378B2 (en) * | 2002-03-07 | 2006-03-07 | Dean Melanie A | Patient conditional diagnosis assessment and symptom tracking system |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| WO2003095448A1 (en) | 2002-05-06 | 2003-11-20 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
| EP1518855B1 (en) | 2002-06-28 | 2011-10-26 | Astellas Pharma Inc. | Diaminopyrimidinecarboxa mide derivative |
| CN103169708B (zh) | 2002-07-29 | 2018-02-02 | 里格尔药品股份有限公司 | 用2,4‑嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法 |
| EP1558609A4 (en) | 2002-10-30 | 2008-05-28 | Merck & Co Inc | KINASE INHIBITORS |
| EA200500721A1 (ru) * | 2002-11-28 | 2005-12-29 | Шеринг Акциенгезельшафт | Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| OA13309A (en) | 2002-12-20 | 2007-04-13 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth. |
| US7109337B2 (en) * | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| SE0203820D0 (sv) * | 2002-12-20 | 2002-12-20 | Astrazeneca Ab | chemical compounds |
| EA011164B1 (ru) | 2003-02-07 | 2009-02-27 | Янссен Фармацевтика Н. В. | Производные пиримидина для профилактики вич-инфекции |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| WO2005003103A2 (en) | 2003-06-30 | 2005-01-13 | Astrazeneca Ab | 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases |
| JP2006528640A (ja) | 2003-07-22 | 2006-12-21 | ニューロジェン・コーポレーション | 置換ピリジン−２−イルアミン類縁体 |
| PT1660458E (pt) | 2003-08-15 | 2012-04-27 | Novartis Ag | 2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário |
| PL1663991T3 (pl) | 2003-09-05 | 2007-04-30 | Pfizer Prod Inc | Selektywna synteza CF3 – podstawionych pirymidyn |
| US7363505B2 (en) * | 2003-12-03 | 2008-04-22 | Pen-One Inc | Security authentication method and system |
| JP2007537230A (ja) * | 2004-05-14 | 2007-12-20 | ファイザー・プロダクツ・インク | 異常細胞増殖の処置用のピリミジン誘導体 |
| MXPA06011658A (es) | 2004-05-14 | 2006-12-14 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento del crecimiento celular anormal. |
| CA2566707A1 (en) * | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| JP2007537238A (ja) * | 2004-05-14 | 2007-12-20 | ファイザー・プロダクツ・インク | 異常細胞増殖の治療のためのピリミジン誘導体 |
| EP1598343A1 (de) | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
| WO2005121121A2 (en) | 2004-06-04 | 2005-12-22 | Arena Pharmaceuticals, Inc. | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| US7872005B2 (en) | 2004-07-01 | 2011-01-18 | Synta Pharmaceuticals Corporation | 2-substituted heteroaryl compounds |
| US7521457B2 (en) * | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| JP2008515986A (ja) | 2004-10-13 | 2008-05-15 | ワイス | Ｎ−ベンゼンスルホニル置換アニリノ−ピリミジン類似物 |
| WO2006053109A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Heteroaryl compounds |
| WO2006053112A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Process for preparing trisubstituted pyrimidine compounds |
| DK1912636T3 (da) | 2005-07-21 | 2014-07-21 | Ardea Biosciences Inc | N-(arylamino)-sulfonamid-inhibitorer af mek |
| US8722884B2 (en) * | 2005-12-01 | 2014-05-13 | Verastem, Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| MEP0908A (xx) | 2005-12-21 | 2010-02-10 | Pfizer Prod Inc | Derivati pirimidina za tretman neprirodnog rasta ćelija |
| GEP20125581B (en) * | 2007-04-18 | 2012-07-25 | Pfizer Prod Inc | Sulfonyl amide derivatives for treatment of abnormal cell growth |
-
2008
- 2008-04-07 GE GEAP200811513A patent/GEP20125581B/en unknown
- 2008-04-07 AU AU2008240359A patent/AU2008240359B2/en active Active
- 2008-04-07 WO PCT/IB2008/000845 patent/WO2008129380A1/en not_active Ceased
- 2008-04-07 NZ NZ580372A patent/NZ580372A/en unknown
- 2008-04-07 BR BRPI0810411A patent/BRPI0810411B8/pt active IP Right Grant
- 2008-04-07 EP EP08719431.2A patent/EP2146779B1/en active Active
- 2008-04-07 ES ES08719431.2T patent/ES2593486T3/es active Active
- 2008-04-07 EA EA200901250A patent/EA016679B1/ru not_active IP Right Cessation
- 2008-04-07 CA CA2684447A patent/CA2684447C/en active Active
- 2008-04-07 CN CN200880019325.7A patent/CN101678215B/zh active Active
- 2008-04-07 AP AP2009005010A patent/AP2009005010A0/xx unknown
- 2008-04-07 DK DK08719431.2T patent/DK2146779T3/en active
- 2008-04-07 KR KR1020097023931A patent/KR101132880B1/ko active Active
- 2008-04-07 CN CN201410067096.3A patent/CN103951658B/zh active Active
- 2008-04-07 JP JP2010503606A patent/JP4782239B2/ja active Active
- 2008-04-07 UA UAA200910461A patent/UA97834C2/ru unknown
- 2008-04-07 MX MX2009011090A patent/MX2009011090A/es active IP Right Grant
- 2008-04-15 CL CL200801076A patent/CL2008001076A1/es unknown
- 2008-04-16 UY UY31026A patent/UY31026A1/es not_active Application Discontinuation
- 2008-04-16 PA PA20088777101A patent/PA8777101A1/es unknown
- 2008-04-17 US US12/105,151 patent/US7928109B2/en active Active
- 2008-04-17 PE PE2008000674A patent/PE20090434A1/es not_active Application Discontinuation
- 2008-04-17 TW TW097113908A patent/TWI369205B/zh active
- 2008-04-18 AR ARP080101626A patent/AR066125A1/es not_active Application Discontinuation
-
2009
- 2009-10-12 IL IL201468A patent/IL201468A/en not_active IP Right Cessation
- 2009-10-16 CU CU20090175A patent/CU23813A3/es not_active IP Right Cessation
- 2009-10-16 NI NI200900190A patent/NI200900190A/es unknown
- 2009-10-16 MA MA32288A patent/MA31319B1/fr unknown
- 2009-10-16 DO DO2009000248A patent/DOP2009000248A/es unknown
- 2009-10-16 GT GT200900272A patent/GT200900272A/es unknown
- 2009-10-16 CO CO09115844A patent/CO6260093A2/es not_active Application Discontinuation
- 2009-10-16 TN TNP2009000428A patent/TN2009000428A1/fr unknown
- 2009-10-16 EC EC2009009694A patent/ECSP099694A/es unknown
-
2011
- 2011-03-11 US US13/045,923 patent/US8247411B2/en active Active
-
2012
- 2012-07-24 US US13/557,049 patent/US8440822B2/en active Active
-
2013
- 2013-03-29 US US13/853,483 patent/US20140100368A1/en not_active Abandoned
-
2014
- 2014-05-08 IL IL232511A patent/IL232511B/en active IP Right Grant
- 2014-11-24 US US14/552,153 patent/US20150080368A1/en not_active Abandoned
-
2016
- 2016-01-19 US US15/000,944 patent/US20160130250A1/en not_active Abandoned
- 2016-09-12 US US15/263,041 patent/US20170001981A1/en not_active Abandoned
-
2017
- 2017-04-20 US US15/492,719 patent/US20170327485A1/en not_active Abandoned
-
2018
- 2018-04-05 US US15/946,117 patent/US10450297B2/en active Active
- 2018-07-12 IL IL260560A patent/IL260560B/en active IP Right Grant
-
2019
- 2019-09-11 US US16/567,675 patent/US20200002310A1/en not_active Abandoned
-
2021
- 2021-08-27 US US17/458,862 patent/US20220251066A1/en not_active Abandoned
-
2023
- 2023-03-15 US US18/121,809 patent/US20240109862A1/en not_active Abandoned
-
2024
- 2024-07-30 US US18/789,272 patent/US20250214963A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010524914A5 (enExample) | ||
| CA2684447A1 (en) | Sulfonyl amide derivatives for the treatment of abnormal cell growth | |
| JP7169412B2 (ja) | 抗癌活性及び抗増殖活性を呈する２－アミノピリミジン－６－オン及び類似体 | |
| JP2016519685A5 (enExample) | ||
| JP2009535335A5 (enExample) | ||
| JP2013056930A5 (enExample) | ||
| JP2015503529A5 (enExample) | ||
| RU2008145662A (ru) | Ингибиторы фосфоинозитид-3-киназы и содержащие их фармацевтические композиции | |
| SI2797918T1 (en) | Bromodomain inhibitors | |
| RU2015148359A (ru) | Хиназолины и азахиназолины - двойные ингибиторы путей ras/raf/mek/erk и pi3k/akt/pten/mtor | |
| JP2009513703A5 (enExample) | ||
| JP2010512337A5 (enExample) | ||
| JP2020515571A5 (enExample) | ||
| JP2014514317A5 (enExample) | ||
| JP2014513704A5 (enExample) | ||
| CA2651363A1 (en) | Triazolopyrazine derivatives useful as anti-cancer agents | |
| JP2012512887A5 (enExample) | ||
| RU2009125916A (ru) | Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения | |
| RU2014112345A (ru) | Хинолил-содержащее соединение гидроксамовой кислоты, способ его получения, фармацевтическая композиция, содержащая это соединение, и его применение | |
| JP2005518382A5 (enExample) | ||
| JP2016525078A5 (enExample) | ||
| SI2824100T1 (en) | 1,2,5-oxadiazoles as inhibitors of indolamine 2,3-dioxygenase | |
| RU2014101464A (ru) | Циклопропил-конденсированные-1,3-тиазепины в качестве ингибиторов васе 1 и(или) васе 2 | |
| JP2017532360A5 (enExample) | ||
| JP2017512786A5 (enExample) |